Human Fungal Infection, Immune Response, and Clinical Challenge-a Perspective During COVID-19 Pandemic

Area of Science:

• Medical Mycology
• Immunology
• Infectious Diseases

Background:

• Fungi are part of the human microbiota but can cause opportunistic infections.
• COVID-19 patients, especially those with predisposing conditions or on immunosuppressive medications, face increased risk of severe fungal coinfections.
• SARS-CoV-2 infection can lead to unstable mycobiomes and long-term dysbiosis.

Purpose of the Study:

• To review the challenges and concerns associated with fungal coinfections in COVID-19 patients.
• To discuss the immunological interplay between COVID-19 and fungal pathogens.
• To highlight the impact of treatments like corticosteroids on fungal infections and the growing issue of antifungal resistance.

Main Methods:

• Literature review summarizing current understanding of fungal coinfections in COVID-19.
• Analysis of immunological responses involving pattern recognition receptors (PRRs), pathogen-associated molecular patterns (PAMPs), Toll-like receptors (TLRs), and NOD-like receptors (NLRs).
• Discussion on the clinical implications of treatments and the emergence of antifungal resistance.

Main Results:

• Simultaneous COVID-19 and fungal infections can hyperactivate immune cells, leading to cytokine storms.
• Corticosteroid use in severe COVID-19 may promote systemic fungal infections.
• Antifungal treatments like amphotericin B are recommended but face challenges due to drug resistance.

Conclusions:

• Fungal coinfections represent a significant threat to COVID-19 patient outcomes.
• Effective management requires addressing immune dysregulation, treatment side effects, and evolving antifungal resistance.
• There is an urgent need for new strategies to combat this impending health crisis.